CerebroSpinal Fluid (CSF) Leak
Conditions
Keywords
SIH, PDPH, Spinal leaks, CSF leak, SLEC, Spontaneouse Intercranial Hypotension, CSF-venous fistula, Post Dural Puncture Headache, Cerebrospinal Fluid Leak, Rare disease
Brief summary
Spinal CSF leaks are considered as rare disease. They cause a variety of symptoms, mainly culminating in a chronic headache syndrome. Crucially, yet often disregarded, the disease holds the potential for cure. The multitude of symptoms, and their inconsistency over time are just two of many challenges preventing timely diagnosis and treatment in many patients. Spinal CSF leaks can occur after intentional or accidental dural puncture (post-dural puncture headache - PDPH) or spontaneously (spontaneous intracranial hypotension - SIH). Awareness is steadily increasing with simultaneous increase of recognized patients. Yet, research and diagnostic is mainly provided by few specialized centers, as e.g. Freiburg. Thus, many observations point towards a large non-diagnosed and non-recognized number of patients, most likely being misdiagnosed and mistreated. Objective: The aim of the registry is to collect structured information on the frequency, cause, symptoms, diagnostic procedures, treatment options and long-term outcome. With the help of the registry, we would like to contribute to a better understanding and treatment of the diseases. Methods: Prospective, longitudinal registry on patients with suspected SIH or PDPH, including data on demographics, clinical presentation, diagnostic findings, treatment, at treatment outcome.
Detailed description
Spinal CSF leaks have a severe impact on quality of life and health. Symptoms vary from chronic headache syndrome to intracranial bleeding, cognitive decline, and coma. Crucially, yet often disregarded, the disease holds the potential for cure. Lumbar dural leaks can arise from commonly performed medical interventions such as diagnostic lumbar punctures, spinal anesthesia, spinal infiltrations, or incidental dural punctures during epidural analgesia in obstetric care, resulting in post-dural puncture headache (PDPH). Additionally, a notable fraction of spinal CSF leaks manifests as spontaneous intracranial hypotension (SIH), which derives from different types of spontaneous leaks along the Spine and remains broadly under-recognized. The main clinical symptoms of spinal CSF leaks are orthostatic headaches with a most often defined beginning, typically accompanied by hearing impairment and dizziness, worsened by exercise and movement. Additionally, other manifestations are known, such as cognitive decline, bilateral brachial amyotrophy, paradox headache, fatigue, and many more. In patients presenting with spinal CSF leaks, the accurate diagnosis often eludes clinicians, leading to frequent misdiagnoses of chronic migraine, fatigue, or psychiatric conditions. Many patients endure months, if not years, before a diagnosis of a treatable condition is finally established. The heterogeneity of the symptoms can appear inconsistent or even paradoxical, posing diagnostic challenges. The extent of possible long-term deterioration is not recognized. The reported incidence of PDPH fluctuates considerably, ranging from 2 to 40 per 100 procedures performed. This variance is influenced by patient-related factors (e.g., age, gender, pregnancy status) and procedural factors (e.g., needle size and type). PDPH, according to current criteria, occurs within 5 days after a dural puncture. Nevertheless, there are widely underestimated pitfalls: a dural puncture is not always recognized by the person performing an epidural procedure, symptoms can occur after more than 5 days, and disease courses can be chronic. These facts are widely unknown, leading to largely hidden figures of patients being under or misdiagnosed and, thus, not treated. Moreover, PDPH is primarily observed following unintentional dural puncture during the administration of obstetric anaesthesia and analgesia to parturients. Spontaneous intracranial hypotension (SIH) can be caused by ventral, lateral, or sacral spinal leaks or by CSF-venous fistulae, which was first described in 2014. An annual incidence rate of \ 4/100,000 was estimated in 2022. This rate is likely underestimated as it only includes confirmed cases, thus recognized cases within a widely non-recognized entity. Often, patients are neither identified nor directed to the appropriate MRI, which, in numerous instances, could lead to the correct diagnosis. Even when SIH is identified, non-targeted epidural blood patches in the lumbar region are often not administered due to perceived elevated risks. An epidural blood patch might be able to help to heal the leak. At the same time, it must be noted that even long-term improvement does not necessarily indicate closure of the leak and prevention of long-term sequelae, such as superficial siderosis. Invasive diagnostics are not employed to pinpoint the location, and treatment to seal the leak is not consistently pursued. The effects of treatment are often immediate and can be successful even in chronic patients. Evidence shows that leaks are held open by new membranes (Neo-membranes) that prevent spontaneous healing. Thus, the correct localization of such a leak and targeted sealing or close follow-ups should be initiated. The management approaches for SIH and PDPH significantly deviate from standard pain management strategies employed for other types of headaches. Noteworthy interventions include the application of blood patches and even surgical measures to seal the leak, offering curative solutions. Those enduring chronic spinal CSF leaks experience profound limitations in their health-related quality of life, comparable to those with chronic immunological diseases or cancer. Overlooking the diagnosis and management of spinal CSF leaks may precipitate progressive deterioration, with the potential for persistent sequelae like superficial siderosis, syndromes mimicking frontotemporal dementia (FTD), and chronic subdural hematoma formation. This registry aims to set ground for standardized, prospective demographic, diagnostic and treatment data assessments, and patient self-reported outcome measures. Collecting this data is essential to potentially exploring risk factors, understanding outcome predictors, and refining diagnostics. Additionally, standardized data collection will allow the appropriate designing of urgently needed randomized trials. Aims: Primary aim: To describe the proportion of patients diagnosed with SIH or PDPH Secondary aims: 1. To describe the proportion of different spinal CSF leaks observed per entity 2. To describe the demographics per entity, and per different spinal CSF leak type 3. To describe the clinical spectrum per entity, and per different spinal CSF leak type 4. To describe the imaging features per entity, and per different spinal CSF leak type 5. To describe the outcome of different treatments, and per different spinal CSF leak type 6. To describe the adverse events of different treatments, and per different spinal CSF leak type 7. To explore potential diagnostic markers per entity, and per different spinal CSF leak type 8. To explore risk factors per entity, and per different spinal CSF leak type 9. To evaluate differences between spinal CSF leak types regarding age, sex, BMI, clinical presentation, diagnostic findings 10. To assess the effect of disease duration on imaging findings, and on outcome after persistent closure of a leak Method: The registry is prospective, longitudinal and currently monocentric\*. Diagnostic, treatment, and follow-up procedures follow clinical standard operating procedures (SOP) according to the suspected diagnosis and the clinical findings. Routinely assessed data of the initial diagnostic workup and the individual's disease course with or without treatment will be collected over 2 years per individual. The investigators' semi-annual meetings ensure the achievement of the register's predefined aims. There are no specific risks or benefits for the patients participating in this registry. Any procedure will be performed according to clinical standards as indicated. There will be no additional visits to the hospital or the ambulatory. There will be no additional imaging performed, especially no additional radiation. A merely intrinsic benefit might exist for the patient supporting this study and supporting medical research. As this is an explorative and observational study on rare diseases without formal sample size estimation, we limit the study by time of duration (10 years). Patients suffering from rare diseases most often face delays in diagnostics and treatments. To underscore this known burden: By an estimated population of 1.74 Mio in the Freiburg area and an incidence rate of SIH of about 5/100.0004, approximately 85 patients should be expected per year stemming from this area. Freiburg is the only center offering adequate diagnostic pipelines for these patients. Despite the increasing awareness, the number of patients diagnosed in the area adjunct to the Freiburg CSF center is within a range of 15 to 20 patients per year, thus still too low compared to the expected number with many patients unrecognized, and or underdiagnosed. Our current numbers of confirmed SIH treatments range from 100 per year with patients being referred throughout Germany and about 15-20 international patients per year. We expect this rate to rise within the next few years. The number of PDPH patients with a focus on persistent PDPH patients is currently rapidly increasing. We see about 40-60 per year. Interim-Evaluation of the Registry's primary and secondary descriptive aims will be performed and reported as a step-wise, dynamic approach: * After each +100 patients with confirmed SIH * After each +50 patients with confirmed PDPH The secondary objectives, which involve comparisons, the exploration of diagnostic markers, and risk factors, will be addressed using a dynamic biostatistical model: The analysis will only be conducted after a power analysis deems the observed sample adequate. Proportions will be presented as a percentage with 95% confidence interval (CI). The sata of patients with different types of spinal CSF leaks will be summarized using descriptive statistics, i.e. median and quartiles for continuous and absolute and relative frequencies for categorical variables, regarding their clinical, laboratory, and diagnostic findings, and number of diagnostic and therapeutic procedures needed. Furthermore, the proportion of SIH patients with different spinal CSF leak types 1. will be compared between males and females using a Chi2-Test and a risk difference with 95% CI. 2. Will be presented by age groups (per two decades), and per sex as a percentage with a 95% Wilson confidence interval (CI). Age, sex, BMI, clinical presentation, and diagnostic findings between different spinal CSF leaks will be compared using the Mann-Whitney-Wilcoxon test and Chi2 test for continuous and categorical variables, respectively. A multivariable logistic regression for the presence of SIH, PDPH, and chronic PDPH, respectively, will be constructed using the clinical and diagnostic parameters with some evidence for a difference according to the presence of a spinal CSF leak (p \< 0.2). The potential nonlinearity of the age effect is evaluated based on a residual analysis of the regression model. Odds ratios with 95% CI will be reported. Using bootstrapping, we will present a ROC curve and AUC with 95% Due to the exploratory approach,, no correction for multiple testing will be performed. A multivariable linear regression for imaging findings (especially Bern Score, presence of SLEC, vand olumetries), and for the patient-reported outcomes will be constructed using the clinical and diagnostic parameters at admission with some evidence for a difference (p\<0.2). Adjusted R-squares, Beta-coefficients with 95% CI, standard errors will be reported.
Interventions
None listed
Sponsors
Study design
Eligibility
Inclusion criteria
1. Patients with suspected spinal CSF leak based on one of the following * History of new orthostatic symptomes with or without prior spinal procedure * Imaging suggestive for spinal CSF leak 2. Informed consent
Exclusion criteria
a) Symptoms beeing conclusively explained by another known diagnosis
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Primary Diagnosis given after primary workup (yes/no) | up to 4 weeks after inclusion | * SIH (fulfilling ICHD-3 criteria) - yes/no * atypical SIH - yes/on * Asymptomatic SIH (positive imaging signs only) - yes/no * PDPH (fulfilling ICHD-3-criteria) - yes/no * persistentPDPH - yes/no |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| SIH/PDPH - weight | at time of inclusion | kilogram (kg) |
| SIH/PDPH - lumbar infusion test - pressure at tilt up 10° | up to 4 weeks after inclusion | mmHg |
| SIH/PDPH - Severeness of shoulder- and neck pain | at time of inclusion | \- in 0 to 10, 10 being most severe |
| SIH/PDPH - severeness of nausea | at time of inclusion | \- in 0 to 10, 10 being most severe |
| SIH/PDPH - severeness of hearing disturbances and tinnitus | at time of inclusion | \- in 0 to 10, 10 being most severe |
| SIH/PDPH - severeness of cognitive deficits | at time of inclusion | \- in 0 to 10, 10 being most severe |
| SIH/PDPH - severeness of visual disturbances | at time of inclusion | \- in 0 to 10, 10 being most severe |
| SIH/PDPH - . ability to focus and concentrate | at time of inclusion | rated between 0 to 5, with 5 indicating highest burden |
| SIH/PDPH - MRI spine: Spinal longitudinal extradural fluid collection (SLEC) (yes/no) | up to 4 weeks | — |
| SIH/PDPH - MRI-spine: DiverTICula (TIC) ≥8mm (yes/no) | up to 4 weeks | number of TICs ≥8mm |
| SIH/PDPH - Volumetry of epidural spinal veins at C2 | up to 4 weeks | mm\^3 |
| SIH/PDPH - MRI spine: Enlarged cervical epidural spinal veins at C2 | up to 4 weeks | yes/no |
| SIH/PDPH - lumbar infusion test - pressure at tilt down | up to 4 weeks after inclusion | mmHg |
| SIH/PDPH - height | at time of inclusion | height in meter (m) |
| SIH/PDPH - lumbar infusion test - pressure at tilt up 30° | up to 4 weeks after inclusion | mmHg |
| SIH/PDPH - lumbar infusion test - pressure at plateau | up to 4 weeks after inclusion | mmHg |
| SIH/PDPH - Laboratory parameters at diagnosis (decriptive) | up to 4 weeks after inclusion | * Routine Blood analysis * Abnormal CSF-analysis |
| SIH/PDPH - Lumbar Infusiontest - amplitude at baseline | up to 4 weeks | mmHg |
| SIH/PDPH - lumbar infusion test - amplitude at tilt down | up to 4 weeks after inclusion | mmHg |
| SIH/PDPH - lumbar infusion test -amplitude at tilt up 10° | up to 4 weeks after inclusion | mmHg |
| SIH/PDPH - lumbar infusion test - amplitude at tilt up 30° | up to 4 weeks after inclusion | mmHg |
| SIH/PDPH - lumbar infusion test - amplitude at plateau | up to 4 weeks after inclusion | mmHg |
| SIH/PDPH - Results of neuropathological tissue analysis if assessed (descriptive) | up to 6 weeks | epidural membranes (descriptive) arachnoid funnels (descriptive) diverticula (descriptive) epidural vessels (descriptive) |
| SIH/PDPH - phase-contrast MRI : CSF-velocity | up to 4 weeks | cm/s |
| SIH/PDPH - phase-contrast MRI: Stroke-volume CSF | up to 4 weeks | ml |
| SIH/PDPH - phase-contrast MRI: Spinal cord motion | up to 4 weeks | mm |
| SIH/PDPH - phase-contrast MRI: Spinal cord velocities | up to 4 weeks | cm/s |
| SIH/PDPH - MRI spine: Bud-on-branching sign (yes/no) | up to 4 weeks | — |
| SIH/PDPH - MRI spine: Localized flow-voids in sagittal spine T2 images (yes/no) | up to 4 weeks | — |
| SIH/PDPH - modified Ranking scale | at time of inclusion | range in 0-6, 0 indicating best health |
| SIH/PDPH - Experience of the local team | at time of inclusion | Number of patient with suspicion for SIH work-up/year |
| SIH/PDPH - Patients' demographics | at time of inclusion | Country, City |
| SIH - Previously received treatment at time of inclusion (yes/no) | at time of inclusion | Medical SIH treatment, Other symptomatic treatment, Untargeted lumbar blood patch, Targeted blood patch, Targeted fibrin patch, Endovascular embolization, Minimally invasive surgery, Open surgery - dorsal approach, Open surgery-ventral approach, Open surgery-transforaminal approach, Discectomy, Laminectomy, Stabilization procedures, Surgery, other techniques |
| SIH/PDPH - sex | at time of inclusion | male female diverse |
| SIH/PDPH - age | at time of inclusion | years |
| SIH/PDPH - pre-existing Neurological deficits (yes/no) | at time of inclusion | Neurological deficits due to previously attempted treatments at the time of inclusion |
| SIH/PDPH - Neurological deficits in routine clinical testing | at time of inclusion | descriptive |
| SIH - Montreal cognitive Assessment | at time of inclusion | range 0-30, 30 indicating best performance |
| SIH - Trail-making test part B | at time of inclusion | in minutes needed to fulfill the task |
| PDPH -BMI | at time of inclusion | kg/m\^2 |
| SIH/PDPH - Regular use of stimuli > 6 months (yes/no) | at time of inclusion | Nicotine, Alcohol, Recreational drugs |
| SIH/PDPH - Headache-Impact-Test (HIT)-6 | at time of inclusion | Headache-Impact-Test (HIT)-6 range 36 to 78 points, 78 indicating highest impact of headaches. |
| SIH/PDPH - 5 dimensions /5 levels European Quality of life questionaire (EQ-5D-5L) Index | at time of inclusion | \<0 to 1, with 1 indicating unimpaired health |
| SIH/PDPH - Self-Administered Comorbidity Questionaire (SCQ) | at time of inclusion | 13-item Self-Adminestered Comorbidity Questionaire (SCQ), range 0 to 39, 0 indicating lowest burden |
| PDPH - Patient'S Global Impression of Change (PIGC) | at time of inclusion | range 7 - 42, 7 indicating highest improvement |
| SIH - Opening pressure on lumbar puncture if performed (not recommended in routine), or myelogram | up to 4 weeks | cmH2O |
| SIH/PDPH - Total Bern-Score MRI head according to Dobrocky et al. | up to 4 weeks | range 0 to 9 with 9 indicating highest likelihood of a spinal CSF leak |
| SIH/PDPH - Subitems Bern-Score MRI head according to Dobrocky et al. | up to 4 weeks | Meningeal enhancement (yes/no), Subdural fluid (yes/no), Venous Distention (yes/no), Effaced suprasellar distance (yes/no), Effaced mamillopontine distance (yes/no), Effaced prepontine distance (yes/no) |
| SIH - MRI head - Superficial Siderosis | up to 4 weeks | (yes/no) |
| SIH - MRI head - Layered calvarial hyperostosis | up to 4 weeks | (yes/no) |
| SIH - Sinus vein thrombosis | up to 4 weeks | (yes/no) |
| SIH/PDPH - Volumetry of the CSF-space MRI head & spine | up to 4 weeks | mm\^3 |
| SIH/PDPH - Volumetry of the CNS MRI head & spine | up to 4 weeks | mm\^3 |
| SIH/PDPH - Imaging Density score | up to 4 weeks | Density scores of the intracranial compartments MRI head & spine |
| SIH/PDPH - Total radiation dose applied per diagnostic procedure with radiation performed | at primary workup | Sievert |
| SIH - Myelography number | up to 24 weeks | Number of myelographies performed for precise localization |
| SIH - Type of myelography technique applied (yes/no) | up to 4 weeks | conventional,digital subtraction, dynamic CT, Cone-beam CT, Photon-counting CT, fluoroscopy, Other (specify) |
| SIH - Adverse events during myelography (yes/no) | up to 4 weeks | nausea, dizziness/vertigo, emesis, allergic reaction, seizure, treatment intensive care unit (independent of cause)) |
| SIH - Headache before and after myelogram | up to 4 weeks | in 0-10, 10 numeric rating scale |
| SIH - Positioning during index myelography that proofs the leak (yes/no) | up to 4 weeks | prone, lateral decubitus, supine |
| SIH - myelography that proofs the leak performed applying (yes/no) | up to 4 weeks | resisted insipration, pressuization, valsalva maneuver |
| SIH/PDPH - Lumbar Infusiontest - Pressure at baseline | up to 4 weeks | pressure (mmHg) |
| SIH/PDPH - Lumbar Infusiontest - Resistence to CSF outflow (Rcsf) | up to 4 Weeks | mmHg/(ml/min) |
| SIH/PDPH - Lumbar Infusiontest - Elastance | up to 4 weeks | Elastance coefficient (1/ml) |
| SIH/PDPH - Lumbar Infusiontest - Pressure-Volume-Index | up to 4 weeks | ml |
| SIH/PDPH - Lumbar Infusiontest - Needle resistance | up to 4 weeks | — |
| SIH/PDPH - PET-CT - Evidence of CSF-loss (yes/no) | up to 4 weeks | — |
| SIH/PDPH - PET-CT if performed - | up tp 4 weeks | half-life of the tracer in the CSF space (minutes) |
| SIH/PDPH - Laboratory parameters at diagnosis (normal/abnormal) | up to 4 weeks after inclusion | * complete routine Blood analysis (including: cellcount, electrolytes, coagulation, renal function, thyroid marker) (normal/abnormal) * complete routine CSF-analysis (including: cell count, protein) (normal/abnormal) |
| SIH - CSF leak types identified by dynamic myelography (yes/no) | up to 4 weeks | * Ventral dural leak * Lateral dural leak * CSF-venous fistula, single * CSF-venous fistula, multiple * Sacral dural leak * CSF-lymphatic fistula * Dorsal dural leak * Undefined |
| SIH - Multiples leaks (yes/no) | up to 4 weeks | — |
| SIH - Level of spinal CSF leak (spinal segment) and side in myelogram | up to 4 weeks | — |
| SIH - In case of surgery: spinal segment and side confirmed? (yes/no) | up to 4 weeks | — |
| SIH/PDPH - Experience of leading interventionalist in SIH-diagnostics/year | up to 4 weeks | — |
| SIH/PDPH - Disease duration at time of therapy | up to 4 weeks | month |
| SIH/PDPH - Therapy performed after CSF leak diagnosis (yes/no) | up to 4 weeks | Untargeted lumbar blood patch, Targeted blood patch, Targeted fibrin patch, Endovascular embolization, Minimally invasive surgery with patching, Minimally invasive surgery with clipping, Minimally invasive surgery with disconnection, Open surgery, dorsal approach, Open surgery, ventral approach, Open surgery, transforaminal approach, Surgery, other techniques, Medical PDPH treatment, Other symptomatic treatment, e.g. infiltration N. occipitalis, Untargeted lumbar platelet-rich fibrin patch |
| SIH/PDPH - Experience of leading surgeon in SIH/PDPH-surgeries/year | up to 4 weeks or longer, depending on the number of surgeries | in numbers of SIH/PDPH-surgeries/year |
| SIH/PDPH - Interventions needed addressing secondary complications of spinal CSF leaks, especially chronic subdural hematoma | up to 4 weeks | Twist drill craniostomy (yes/no), Burr hole craniostomy (yes/no ), Mini craniotomy (yes/no), Conventional trepanation (yes/no), Use of drains and any form of controlled lavage (saline and or clot lysis) (yes/no,), Embolization of MMA (middle meningeal arteria) (yes/no), Other intervention (yes/no) |
| PDPH - Event of putative dural puncture | up to 4 weeks | date |
| PDPH - Event of putative dural puncture (yes/ no) | up to 4 weeks | * Diagnostic lumbar puncture * Diagnostic lumbar puncture with drainage in idiopathic intracranial hypertension * Diagnostic lumbar puncture with drainage in idiopathic normal-pressure hydrocephalus * Peridural anesthesia in obstetrics * Spinal anesthesia in obstetrics * Peridural anesthesia, other intervention * Spinal anesthesia, other intervention * Infiltration * others |
| SIH/PDPH - adverse events related to current treatment at discharge (yes/no) | up to 4 weeks | Rebound hypertension, Persistence/Reoccurrence of the leak, Suture insufficiency, Infect (systemic/local), Bleeding, Sensory deficits, Motor deficits, Gait ataxia, Bladder dysfunction, Bowl dysfunction, Others |
| PDPH - Lumbar segment of putative dural puncture known (yes/no) | up to 4 weeks | — |
| PDPH - Puncture under imaging guidance | up to 4 weeks | location truly known |
| PDPH - Duration between (putative) dural puncture until the onset of symptoms | up to 4 weeks | days |
| PDPH - Time to first blood patch | up to 4 weeks | days |
| PDPH - Number of bloodpatches received before admission | up to 4 weeks | — |
| PDPH - Prior treatments at the time of admission (yes/no) | up to 4 weeks | Fluids, Caffeine, Bedrest, Medical treatment, Other treatment, e.g., infiltrations, Untargeted lumbar bloodpatch, Surgery |
| PDPH - Post-dural puncture pseudomeningocele (arachnoid bleb) | up to 4 weeks | (yes/no) |
| PDPH - Spinal Segment location of the arachnoid bleb | up to 4 weeks | — |
| PDPH - Identified CSF leak types by dynamics myelography and/or intraoperatively: | up to 4 weeks | ventral post-dural puncture leak, dorsal post-dural puncture pseudomeningocele (arachnoid bleb), dorsal post-dural puncture leak None |
| PDPH - Intraoperatively Identified membranes (yes/no) | up to 4 weeks | neo-membranes (pseudo dura), webs, funnels |
| PDPH - Dinosaur-tail sign (yes/no) | at time of inclusion | — |
| PDPH - specific segment of identified intraoperative membranes (descriptive) | up to 4 weeks | — |
| PDPH - CSF leak types identified by dynamic myelography and/or intraoperatively | up to 4 weeks | ventral post-dural puncture leak, dorsal post-dural puncture pseudomeningocele (arachnoid bleb), dorsal post-dural puncture leak, None |
| PDPH - Diagnostic procedures performed (yes/no, number) | uo to 4 weeks | CT Head, MRI head, MRI spine, Dynamic digital subtraction myelogram, Dynamic CT-myelogram, Photon-counting CT-myelogram, Cone-beam myelogram, Infusion testing, PET-CT, Other (to exclude/confirm alternative diagnosis) |
| PDPH - Volume lumbar bloodpatch | up to 4 weeks | ml |
| SIH/PDPH - work capacity | at time of inclusion | range 0 to 5, 0 indicating full capacity |
| SIH/PDPH -complaints | at time of inclusion | * current complaints (descriptively) * most stressful complaint (descriptively) |
| SIH/PDPH - headache severity | at time of inclusion | range 0 to 10, 10 indicating most severe pain |
| SIH/PDPH - Days within the last month | at time of inclusion | * with headaches * with pain medication intake in the last month |
| SIH/PDPH - maximum duration being continuously upright | at time of inclusion | hours |
| SIH/PDPH - severeness of dizziness | at time of inclusion | \- in 0 to 10, 10 being most severe |
Other
| Measure | Time frame | Description |
|---|---|---|
| SIH/PDPH - Follow up-Duration of treatment for rebound hypertension after therapy of the CSF leak | 4 weeks after treatment | days |
| SIH/PDPH - Follow up-Average dosage of acetazolamide per day | 4 weeks after treatment | mean mg/d |
| SIH/PDPH - Follow up - Total Bern-Score, according to Dobrocky et al. | 3 months after treatment | range 0 to 9, 9 indicating highest likelihood of spinal CSF leak |
| SIH/PDPH - Follow up - Subitems Bern-Score, according to Dobrocky et al. | 3 months after treatment | * Meningeal enhancement (yes/no) * Subdural fluid (yes/no) * Venous distention (yes/no) * Effaced suprasellar distance (yes/no) * Effaced mamillopontine distance (yes/no) * Effaced prepontine distance (yes/no) |
| SIH/PDPH - Follow up - Spinal longitudinal extradural fluid collection at site of the leak (SLEC) (only if present before) | 3 months after treatment | yes /no |
| SIH/PDPH - Follow up - Headache-Impact-Test (HIT)-6 | 3, 6, 12 & 24 months after treatment | range 36 to 78 points, 78 indicating highest impact of headaches |
| SIH/PDPH - Follow up - 5 dimension/ 5 levels European Quality of life questionnaire (EQ-5D-5L) | 3, 6, 12, & 24 months after treatment | \<0 to1, 1indicating unimpaired health |
| SIH/PDPH - Follow up - Patient's Global Impression of Change (PGIC) | 3, 6, 12 & 24 months after treatment | range 7 to 42, 7 indicating highest improvement |
| SIH/ PDPH - Follow up - Self-administered comorbidity questionnaire (SCQ) | 12 & 24 months after treatment | range 0 to 39, 0 indicating lowest burden |
| SIH/PDPH - follow-up - current working capacity | at 4 weeks & 3, 6, 12 & 24 months | range 0 to 5, 0 indicating full capacity |
| SIH/PDPH - follow-up - complaints | 4 week, 3, 6, 12 & 24 months | * current complaints (descriptively) * most stressful complaint (descriptively) |
| SIH/PDPH - follow-up - headache severity | 4 week, 3, 6, 12 & 24 months | range 0 to 10, 10 indicating most severe pain |
| SIH/PDPH - follow-up - Days within the last month | 4 weeks, 3, 6, 12, 24 months | with headaches with pain medication intake in the last month |
| SIH/PDPH - follow-up - maximum duration being continuously upright | 4 weeks, 3, 6, 12 & 24 months | hours |
| SIH/PDPH - follow-up - severeness of dizziness | 4 weeks, 3, 6, 12 &24 months | \- in 0 to 10, 10 being most severe |
| SIH/PDPH - follow-up - Severeness of shoulder- and neck pain | 4 weeks, 3, 6, 12 & 24 months | in 0 to 10, 10 being most severe |
| SIH/PDPH - follow-up - severeness of nausea | 4 weeks, 3, 6, 12 & 24 months | in 0 to 10, 10 being most severe |
| SIH/PDPH - follow-up - severeness of hearing disturbances and tinnitus | 4 weeks, 3, 6, 12 & 24 months | in 0 to 10, 10 being most severe |
| SIH/PDPH - follow-up - severeness of cognitive deficits | 4 weeks, 3, 6, 12 & 24 months | in 0 to 10, 10 being most severe |
| SIH/PDPH - follow-up - severeness of visual disturbances | 4 weeks, 3, 6, 12 & 24 months | in 0 to 10, 10 being most severe |
| SIH/PDPH - follow-up - exhaustion | 4 weeks, 3, 6,12 &24 months | rated between 0 to 5, with 5 indicating highest burden |
| SIH/PDPH - follow-up - ability to focus and concentrate | 4 weeks, 3, 6, 12 & 24 months | rated between 0 to 5, with 5 indicating highest burden |
| SIH/PDPH - follow-up - phase-contrast MRI: CSF-velocity (if performed) | up to 6 months after treatment | cm/s |
| SIH/PDPH - follow-up - phase-contrast MRI Stroke-volume CSF (if performed) | up to 6 months after treatment | ml |
| SIH/PDPH - follow-up - phase-contrast MRI Spinal cord motion (if performed) | up to 6 months after treatment | mm |
| SIH/PDPH - follow-up - phase-contrast MRI Spinal cord velocity (if performed) | up to 6 months after treatment | cm/s |
| SIH/PDPH - Follow up-Reported adverse events related to treatment (yes/no) | 4 weeks and 3 month after treatment | Rebound hypertension, Reoccurrence of the leak, Suture insufficiency, Bleeding, Sensory deficits, Motor deficits, Gait ataxia, Bladder dysfunction, Bowl dysfunction, Others |
Countries
Germany